Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : calls for kidney disease patients to have continued access to customary care level during COVID-19 crisis

share with twitter share with LinkedIn share with facebook
04/09/2020 | 07:23am EDT

Press release

Fresenius Medical Care, the world's leading provider of dialysis products and services, has released an advisory calling for clinical care principles on access to be upheld for patients with advanced chronic kidney disease if a surge in COVID-19 infections overwhelms the available supply of facilities, caregivers and ventilators.

The Global Medical Advisory on Apportioning Care outlines the company's position on how care should be allotted during and after the pandemic and addresses the differing care standards being articulated by various healthcare systems, groups and governments. It stresses the company's commitment to maintaining uninterrupted healthcare delivery for patients around the world who require renal replacement therapy during the pandemic.

The advisory recognizes that capacity issues may become overwhelming to healthcare systems during the pandemic. However, it calls on 'all authorities to recognize the need to make critical equipment, supplies, facilities and care delivery available to patients with advanced kidney diseases that need lifesaving therapy at all times, including during this COVID-19 disease pandemic.'

Dr. Frank Maddux, Global Chief Medical Officer of Fresenius Medical Care and member of the company's Management Board, said the company stands firmly behind the clinical principle that despite the strain on healthcare resources caused by the pandemic, patients with End Stage Kidney Disease requiring dialysis should be able to continue with their prescribed dialysis treatment frequency. Furthermore, dialysis access surgery or interventions needed by some patients are 'not elective procedures and should be delivered in a timely manner' to prevent potential complications, he added.

The advisory asserts that patients needing renal replacement therapy during the pandemic should still be offered the appropriate treatment that has been agreed in consultation with their physicians. 'These discussions may include mechanical ventilation, dialysis, continuous renal replacement therapies and any other extracorporeal support' advised by a patient's care team, it states.

'People with advanced kidney disease come in varied degrees of health and functional status, but they all want to be productive and active members of their families and communities, and we are doing everything in our power to support their desire for individual choices on the level of care they receive,' said Dr. Maddux. 'We want to avoid population-based decisions on care that may not be in the best interests of the individual person.'

Link to the Global Medical Advisory on Apportioning Care:


Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.


This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


FMC - Fresenius Medical Care AG & Co. KGaA published this content on 09 April 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 April 2020 10:22:03 UTC

share with twitter share with LinkedIn share with facebook
03:57aFMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan remains its Buy rating
10/29FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
10/29FRESENIUS SE : Berenberg maintains a Buy rating
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg reiterates its Buy rating
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from UBS
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Warburg Research sticks Neutral
10/29FRESENIUS SE : Warburg Research remains its Buy rating
10/29FRESENIUS SE : Barclays keeps its Buy rating
10/29FRESENIUS SE : Goldman Sachs remains its Buy rating
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Kepler Cheuvreux remains its Buy rating
More news
Financials (USD)
Sales 2020 21 200 M - -
Net income 2020 1 543 M - -
Net Debt 2020 13 866 M - -
P/E ratio 2020 14,8x
Yield 2020 1,74%
Capitalization 22 634 M 22 604 M -
EV / Sales 2020 1,72x
EV / Sales 2021 1,59x
Nbr of Employees 124 736
Free-Float 65,1%
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 96,13 $
Last Close Price 77,29 $
Spread / Highest target 48,5%
Spread / Average Target 24,4%
Spread / Lowest Target -17,7%
EPS Revisions
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors